ArticleBritish journal of haematology2025
Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Data on late morbidity and survival in nodal peripheral T-cell lymphoma (PTCL) are scarce. This study investigated the incidence, subtype distribution, late morbidity and survival outcomes of nodal PTCL in Finland. The study compared 998 patients with nodal PTCL diagnosed between 2007 and 2019 with matched controls. Data from four nationwide Finnish healthcare registries were used. PTCL not otherwise specified was the most common subtype, with a mean annual incidence of 0.62 (0.45-0.87) per 100 000. The 1-year survival was 34% for patients aged <70 years and 49% for those aged ≥70 years. In the younger group, an increased risk of chronic heart failure (hazard ratio [HR], 4.17 [2.16-8.05]; p < 0.001) was observed after PTCL diagnosis. The risks of pneumonia (HR, 6.47 [4.40-9.53]; p < 0.001 and HR, 2.78 [2.010-3.859]; p < 0.001) and thrombosis (HR, 16.09 [4.22-61.39]; p < 0.001 and HR, 5.34 [2.33 to NA]; p < 0.001) were significantly higher in the younger and older age groups than that in controls. The prognosis of nodal PTCL is poor, and patients have a significantly higher risk of comorbidities than controls, irrespective of age. Therefore, targeted and less toxic treatment modalities are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.